1 week Ago By ABMN Staff
Zynex, Inc. ( NASDAQ:ZYXI – Get Free Report ) CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction dated Thursday, January 2nd.
The stock was sold at an average price of $7.88, for a total value of $78,800.00.
Following the completion of the sale, the chief financial officer now owns 26,299 shares of the company’s stock, valued at $207,236.12. This trade represents a 27.
55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website . Zynex Price Performance Shares of ZYXI opened at $8.
09 on Friday. The company’s fifty day simple moving average is $8.30 and its 200 day simple moving average is $8.
37. Zynex, Inc. has a 1-year low of $7.
15 and a 1-year high of $13.77. The company has a market cap of $257.
63 million, a price-to-earnings ratio of 53.93 and a beta of 0.49.
The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.
66. Zynex ( NASDAQ:ZYXI – Get Free Report ) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.
07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01.
Zynex had a return on equity of 13.05% and a net margin of 2.49%.
The firm had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million.
During the same quarter in the previous year, the business earned $0.10 earnings per share. The business’s revenue was up .
1% compared to the same quarter last year. On average, research analysts forecast that Zynex, Inc. will post 0.
2 earnings per share for the current fiscal year. Institutional Investors Weigh In On Zynex Wall Street Analyst Weigh In A number of analysts have recently commented on ZYXI shares. Royal Bank of Canada cut their price target on Zynex from $12.
00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $17.
00 target price on shares of Zynex in a research report on Friday, December 6th. Check Out Our Latest Stock Report on Zynex About Zynex ( Get Free Report ) Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Featured Stories Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter ..
